Skip to main content
Erschienen in: Acta Diabetologica 6/2018

09.03.2018 | Original Article

Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study

verfasst von: Pierre Yves Benhamou, Erik Huneker, Sylvia Franc, Maeva Doron, Guillaume Charpentier, on behalf of the Diabeloop Consortium

Erschienen in: Acta Diabetologica | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Aims

Improvement in closed-loop insulin delivery systems could result from customization of settings to individual needs and remote monitoring. This pilot home study evaluated the efficacy and relevance of this approach.

Methods

A bicentric clinical trial was conducted for 3 weeks, using an MPC-based algorithm (Diabeloop Artificial Pancreas system) featuring five settings designed to modulate the reactivity of regulation. Remote monitoring was ensured by expert nurses with a web platform generating automatic Secured Information Messages (SIMs) and with a structured procedure. Endpoints were glucose metrics and description of impact of monitoring on regulation parameters.

Results

Eight patients with type 1 diabetes (six men, age 41.8 ± 11.4 years, HbA1c 7.7 ± 1.0%) were included. Time spent in the 70–180 mg/dl range was 70.2% [67.5; 76.9]. Time in hypoglycemia < 70 mg/dl was 2.9% [2.1; 3.4]. Eleven SIMs led to phone intervention. Original default settings were modified in all patients by the intervention of the nurses.

Conclusion

This pilot trial suggests that the Diabeloop closed-loop system could be efficient regarding metabolic outcomes, whereas its telemedical monitoring feature could contribute to enhanced efficacy and safety.
This study is registered at ClinicalTrials.gov with trial registration number NCT02987556.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA (2017) Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol 5:501–512CrossRefPubMed Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA (2017) Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol 5:501–512CrossRefPubMed
2.
Zurück zum Zitat Pettus J, Von Herrath M (2018) The shifting paradigm of a “cure” for type 1 diabetes: is technology replacing immune-based therapies? Acta Diabetol 55:117–120CrossRefPubMed Pettus J, Von Herrath M (2018) The shifting paradigm of a “cure” for type 1 diabetes: is technology replacing immune-based therapies? Acta Diabetol 55:117–120CrossRefPubMed
3.
Zurück zum Zitat Maahs DM, Buckingham BA, Castle JR et al (2016) Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care 39:1175–1179CrossRefPubMedPubMedCentral Maahs DM, Buckingham BA, Castle JR et al (2016) Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care 39:1175–1179CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Hovorka R, Canonico V, Chassin LJ et al (2004) Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 25:905–920CrossRefPubMed Hovorka R, Canonico V, Chassin LJ et al (2004) Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 25:905–920CrossRefPubMed
5.
Zurück zum Zitat Bally L, Thabit H, Kojzar H et al (2017) Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol 5:261–270CrossRefPubMedPubMedCentral Bally L, Thabit H, Kojzar H et al (2017) Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Lancet Diabetes Endocrinol 5:261–270CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat El-Khatib FH, Balliro C, Hillard MA et al (2017) Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet 389:369–380CrossRefPubMed El-Khatib FH, Balliro C, Hillard MA et al (2017) Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet 389:369–380CrossRefPubMed
7.
Zurück zum Zitat Haidar A, Messier V, Legault L, Ladouceur M, Rabasa-Lhoret R (2017) Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: an open-label, randomised, crossover, controlled trial. Diabetes Obes Metab 19:713–720CrossRefPubMed Haidar A, Messier V, Legault L, Ladouceur M, Rabasa-Lhoret R (2017) Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: an open-label, randomised, crossover, controlled trial. Diabetes Obes Metab 19:713–720CrossRefPubMed
8.
Zurück zum Zitat Kropff J, Del Favero S, Place J et al (2015) 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 3:939–947CrossRefPubMed Kropff J, Del Favero S, Place J et al (2015) 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 3:939–947CrossRefPubMed
9.
Zurück zum Zitat Nimri R, Muller I, Atlas E et al (2014) MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 37:3025–3032CrossRefPubMed Nimri R, Muller I, Atlas E et al (2014) MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 37:3025–3032CrossRefPubMed
11.
Zurück zum Zitat Castle JR, DeVries JH, Kovatchev B (2017) Future of automated insulin delivery systems. Diabetes Technol Ther 19:S67–S72CrossRefPubMed Castle JR, DeVries JH, Kovatchev B (2017) Future of automated insulin delivery systems. Diabetes Technol Ther 19:S67–S72CrossRefPubMed
12.
Zurück zum Zitat Keith-Hynes P, Guerlain S, Mize B et al (2013) DiAs user interface: a patient-centric interface for mobile artificial pancreas systems. J Diabetes Sci Technol 7:1416–1426CrossRefPubMedPubMedCentral Keith-Hynes P, Guerlain S, Mize B et al (2013) DiAs user interface: a patient-centric interface for mobile artificial pancreas systems. J Diabetes Sci Technol 7:1416–1426CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Place J, Robert A, Ben Brahim N et al (2013) DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Technol 7:1427–1435CrossRefPubMedPubMedCentral Place J, Robert A, Ben Brahim N et al (2013) DiAs web monitoring: a real-time remote monitoring system designed for artificial pancreas outpatient trials. J Diabetes Sci Technol 7:1427–1435CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Anderson SM, Raghinaru D, Pinsker JE et al (2016) Multinational home use of closed-loop control is safe and effective. Diabetes Care 39:1143–1150CrossRefPubMedPubMedCentral Anderson SM, Raghinaru D, Pinsker JE et al (2016) Multinational home use of closed-loop control is safe and effective. Diabetes Care 39:1143–1150CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat DeSalvo DJ, Keith-Hynes P, Peyser T et al (2014) Remote glucose monitoring in cAMP setting reduces the risk of prolonged nocturnal hypoglycemia. Diabetes Technol Ther 16:1–7CrossRefPubMed DeSalvo DJ, Keith-Hynes P, Peyser T et al (2014) Remote glucose monitoring in cAMP setting reduces the risk of prolonged nocturnal hypoglycemia. Diabetes Technol Ther 16:1–7CrossRefPubMed
17.
Zurück zum Zitat Garg SK, Weinzimer SA, Tamborlane WV et al (2017) Glucose Outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 19:155–163CrossRefPubMedPubMedCentral Garg SK, Weinzimer SA, Tamborlane WV et al (2017) Glucose Outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 19:155–163CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Bally L, Thabit H, Tauschmann M et al (2017) Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. BMJ Open 7:e016738CrossRefPubMedPubMedCentral Bally L, Thabit H, Tauschmann M et al (2017) Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. BMJ Open 7:e016738CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Wang Y, Zhang J, Zeng F et al (2017) “Learning” can improve the blood glucose control performance for type 1 diabetes mellitus. Diabetes Technol Ther 19:41–48CrossRefPubMed Wang Y, Zhang J, Zeng F et al (2017) “Learning” can improve the blood glucose control performance for type 1 diabetes mellitus. Diabetes Technol Ther 19:41–48CrossRefPubMed
23.
Zurück zum Zitat Charpentier G, Benhamou PY, Dardari D et al (2011) The DIABEO software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 study). Diabetes Care 34:533–539CrossRefPubMedPubMedCentral Charpentier G, Benhamou PY, Dardari D et al (2011) The DIABEO software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 study). Diabetes Care 34:533–539CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Farrington C (2017) Hacking diabetes: dIY artificial pancreas systems. Lancet Diabetes Endocrinol 5:332CrossRefPubMed Farrington C (2017) Hacking diabetes: dIY artificial pancreas systems. Lancet Diabetes Endocrinol 5:332CrossRefPubMed
26.
Zurück zum Zitat O’Keeffe DT, Maraka S, Basu A, Keith-Hynes P, Kudva YC (2015) Cybersecurity in artificial pancreas experiments. Diabetes Technol Ther 17:664–666CrossRefPubMedPubMedCentral O’Keeffe DT, Maraka S, Basu A, Keith-Hynes P, Kudva YC (2015) Cybersecurity in artificial pancreas experiments. Diabetes Technol Ther 17:664–666CrossRefPubMedPubMedCentral
Metadaten
Titel
Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study
verfasst von
Pierre Yves Benhamou
Erik Huneker
Sylvia Franc
Maeva Doron
Guillaume Charpentier
on behalf of the Diabeloop Consortium
Publikationsdatum
09.03.2018
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 6/2018
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-018-1123-1

Weitere Artikel der Ausgabe 6/2018

Acta Diabetologica 6/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.